Cargando…
Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study
OBJECTIVE: Exposing tumor antigens to the immune system is the key to ensuring the efficacy of immunotherapy. SBRT is the main way to reveal the specifical antigens of tumors which can enhance the immune response. We aimed to explore the clinical efficacy and safety of Toripalimab combined with Anlo...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065408/ https://www.ncbi.nlm.nih.gov/pubmed/37007075 http://dx.doi.org/10.3389/fonc.2023.1113389 |
_version_ | 1785018102990241792 |
---|---|
author | Chen, Yongbiao Hong, Hanyin Fang, Wenzheng Zhang, Xia Luo, Huachun Chen, Zhijian Yu, Jianda Fan, Weiqiang Chi, Xiaobin Peng, Yonghai |
author_facet | Chen, Yongbiao Hong, Hanyin Fang, Wenzheng Zhang, Xia Luo, Huachun Chen, Zhijian Yu, Jianda Fan, Weiqiang Chi, Xiaobin Peng, Yonghai |
author_sort | Chen, Yongbiao |
collection | PubMed |
description | OBJECTIVE: Exposing tumor antigens to the immune system is the key to ensuring the efficacy of immunotherapy. SBRT is the main way to reveal the specifical antigens of tumors which can enhance the immune response. We aimed to explore the clinical efficacy and safety of Toripalimab combined with Anlotinib for uHCC after SBRT. METHODS: This is a prospective, single-arm, explorative clinical study. uHCC patients with an ECOG PS score of 0–1, Child–Pugh class A or B, and BCLC stage B or C were included and treated with SBRT(8Gy*3) followed by 6-cycle combinational therapy with Toripalimab and Anlotinib. The primary endpoint was progression-free survival (PFS) and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence of treatment-related adverse events (TRAEs). Continuous variables were presented as medians and ranges. Survivals were studied with the Kaplan-Meier method. Categorical data were expressed as n (percentage). RESULTS: Between June 2020 and October 2022, a total of 20 patients with intermediate-advanced uHCC were enrolled. All cases had multiple intrahepatic metastases, or macrovascular invasion, or both, among whom 5 cases with lymph node or distant metastases. Until September 2022, the median follow-up time was 7.2 months (range, 1.1-27.7 months). Median survival time could not be assessed at the moment, based on iRecist, median PFS was 7.4 months (range, 1.1-27.7 months), ORR 15.0%, and DCR 50.0%. 14 patients experienced treatment-related adverse events with an incidence of 70%. The overall survival rates at 18 months and 24 months were 61.1% and 50.9%, respectively. And the progression-free survival rates were 39.3% and 19.7%. CONCLUSION: Exposure of specific antigens of HCC via SBRT may improve the efficacy of combinational therapy with Toripalimab and Anlotinib for uHCC with manageable adverse effects, which deserves further exploration. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov, identifier ChiCTR2000032533. |
format | Online Article Text |
id | pubmed-10065408 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100654082023-04-01 Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study Chen, Yongbiao Hong, Hanyin Fang, Wenzheng Zhang, Xia Luo, Huachun Chen, Zhijian Yu, Jianda Fan, Weiqiang Chi, Xiaobin Peng, Yonghai Front Oncol Oncology OBJECTIVE: Exposing tumor antigens to the immune system is the key to ensuring the efficacy of immunotherapy. SBRT is the main way to reveal the specifical antigens of tumors which can enhance the immune response. We aimed to explore the clinical efficacy and safety of Toripalimab combined with Anlotinib for uHCC after SBRT. METHODS: This is a prospective, single-arm, explorative clinical study. uHCC patients with an ECOG PS score of 0–1, Child–Pugh class A or B, and BCLC stage B or C were included and treated with SBRT(8Gy*3) followed by 6-cycle combinational therapy with Toripalimab and Anlotinib. The primary endpoint was progression-free survival (PFS) and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence of treatment-related adverse events (TRAEs). Continuous variables were presented as medians and ranges. Survivals were studied with the Kaplan-Meier method. Categorical data were expressed as n (percentage). RESULTS: Between June 2020 and October 2022, a total of 20 patients with intermediate-advanced uHCC were enrolled. All cases had multiple intrahepatic metastases, or macrovascular invasion, or both, among whom 5 cases with lymph node or distant metastases. Until September 2022, the median follow-up time was 7.2 months (range, 1.1-27.7 months). Median survival time could not be assessed at the moment, based on iRecist, median PFS was 7.4 months (range, 1.1-27.7 months), ORR 15.0%, and DCR 50.0%. 14 patients experienced treatment-related adverse events with an incidence of 70%. The overall survival rates at 18 months and 24 months were 61.1% and 50.9%, respectively. And the progression-free survival rates were 39.3% and 19.7%. CONCLUSION: Exposure of specific antigens of HCC via SBRT may improve the efficacy of combinational therapy with Toripalimab and Anlotinib for uHCC with manageable adverse effects, which deserves further exploration. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov, identifier ChiCTR2000032533. Frontiers Media S.A. 2023-03-17 /pmc/articles/PMC10065408/ /pubmed/37007075 http://dx.doi.org/10.3389/fonc.2023.1113389 Text en Copyright © 2023 Chen, Hong, Fang, Zhang, Luo, Chen, Yu, Fan, Chi and Peng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Chen, Yongbiao Hong, Hanyin Fang, Wenzheng Zhang, Xia Luo, Huachun Chen, Zhijian Yu, Jianda Fan, Weiqiang Chi, Xiaobin Peng, Yonghai Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study |
title | Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study |
title_full | Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study |
title_fullStr | Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study |
title_full_unstemmed | Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study |
title_short | Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study |
title_sort | toripalimab in combination with anlotinib for unresectable hepatocellular carcinoma after sbrt: a prospective, single-arm, single-center clinical study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065408/ https://www.ncbi.nlm.nih.gov/pubmed/37007075 http://dx.doi.org/10.3389/fonc.2023.1113389 |
work_keys_str_mv | AT chenyongbiao toripalimabincombinationwithanlotinibforunresectablehepatocellularcarcinomaaftersbrtaprospectivesinglearmsinglecenterclinicalstudy AT honghanyin toripalimabincombinationwithanlotinibforunresectablehepatocellularcarcinomaaftersbrtaprospectivesinglearmsinglecenterclinicalstudy AT fangwenzheng toripalimabincombinationwithanlotinibforunresectablehepatocellularcarcinomaaftersbrtaprospectivesinglearmsinglecenterclinicalstudy AT zhangxia toripalimabincombinationwithanlotinibforunresectablehepatocellularcarcinomaaftersbrtaprospectivesinglearmsinglecenterclinicalstudy AT luohuachun toripalimabincombinationwithanlotinibforunresectablehepatocellularcarcinomaaftersbrtaprospectivesinglearmsinglecenterclinicalstudy AT chenzhijian toripalimabincombinationwithanlotinibforunresectablehepatocellularcarcinomaaftersbrtaprospectivesinglearmsinglecenterclinicalstudy AT yujianda toripalimabincombinationwithanlotinibforunresectablehepatocellularcarcinomaaftersbrtaprospectivesinglearmsinglecenterclinicalstudy AT fanweiqiang toripalimabincombinationwithanlotinibforunresectablehepatocellularcarcinomaaftersbrtaprospectivesinglearmsinglecenterclinicalstudy AT chixiaobin toripalimabincombinationwithanlotinibforunresectablehepatocellularcarcinomaaftersbrtaprospectivesinglearmsinglecenterclinicalstudy AT pengyonghai toripalimabincombinationwithanlotinibforunresectablehepatocellularcarcinomaaftersbrtaprospectivesinglearmsinglecenterclinicalstudy |